An engineered IL-2 partial agonist promotes CD8+ T cell stemness.

MLA

Mo, Fei, et al. “An Engineered IL-2 Partial Agonist Promotes CD8+ T Cell Stemness.” Nature, vol. 597, no. 7877, Sept. 2021, pp. 544–48. EBSCOhost, https://doi.org/10.1038/s41586-021-03861-0.

APA

Mo, F., Yu, Z., Li, P., Oh, J., Spolski, R., Zhao, L., Glassman, C. R., Yamamoto, T. N., Chen, Y., Golebiowski, F. M., Hermans, D., Majri-Morrison, S., Picton, L. K., Liao, W., Ren, M., Zhuang, X., Mitra, S., Lin, J.-X., Gattinoni, L., & Powell, J. D. (2021). An engineered IL-2 partial agonist promotes CD8+ T cell stemness. Nature, 597(7877), 544–548. https://doi.org/10.1038/s41586-021-03861-0

Chicago

Mo, Fei, Zhiya Yu, Peng Li, Jangsuk Oh, Rosanne Spolski, Liang Zhao, Caleb R. Glassman, et al. 2021. “An Engineered IL-2 Partial Agonist Promotes CD8+ T Cell Stemness.” Nature 597 (7877): 544–48. doi:10.1038/s41586-021-03861-0.